APO Research
Talk to an analyst

APO RESEARCH · REPORT

Inactivated Influenza Virus Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Inactivated Influenza Virus Vaccine Industry Growth and Trends Forecast to 2032

29 December 2025114 pages

Choose your research edition.

Industry ResearchInactivated Influenza Virus Vaccine Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Inactivated Influenza Virus Vaccine Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Inactivated Influenza Virus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Inactivated Influenza Virus Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Inactivated Influenza Virus Vaccine Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Inactivated Influenza Virus Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Inactivated Influenza Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Inactivated Influenza Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Inactivated Influenza Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Inactivated Influenza Virus Vaccine include CSL, Zhejiang Tian Yuan Biopharmaceutical Co., Ltd, Changchun Institute of Biological Products Co., Ltd, Shanghai Institute of Biological Products Co., Ltd, Johnson & Johnson, Mylan, Lanzhou Institute of Biological Products Co., Ltd, Jiangsu Kangrun Biotechnology Co., Ltd and Jiangsu Jindik Biotechnology Co., Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Inactivated Influenza Virus Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Inactivated Influenza Virus Vaccine market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Inactivated Influenza Virus Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Inactivated Influenza Virus Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Inactivated Influenza Virus Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Inactivated Influenza Virus Vaccine Market by Company

CSL

Zhejiang Tian Yuan Biopharmaceutical Co., Ltd

Changchun Institute of Biological Products Co., Ltd

Shanghai Institute of Biological Products Co., Ltd

Johnson & Johnson

Mylan

Lanzhou Institute of Biological Products Co., Ltd

Jiangsu Kangrun Biotechnology Co., Ltd

Jiangsu Jindik Biotechnology Co., Ltd

Pfizer

Hualan Bio Vaccines Co., Ltd

GSK

Dalian Yalifeng Biopharmaceutical Co., Ltd

Beijing Kexing Biological Products Co., Ltd

Emmi Chengxin Biopharmaceutical Co., Ltd

AstraZeneca

Sanofi Pasteur

Inactivated Influenza Virus Vaccine Segment by Type

Whole Virus Vaccine

Subunit Vaccine

Inactivated Influenza Virus Vaccine Segment by Application

Hospital

Clinic

Inactivated Influenza Virus Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Influenza Virus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Inactivated Influenza Virus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Influenza Virus Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Inactivated Influenza Virus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Whole Virus Vaccine Table 2. Major Company of Subunit Vaccine Table 3. Global Inactivated Influenza Virus Vaccine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 5. Global Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Type (2021-2026) Table 6. Global Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (US$ Million) Table 7. Global Inactivated Influenza Virus Vaccine Sales Market Share in Value by Type (2021-2026) Table 8. Global Inactivated Influenza Virus Vaccine Price by Type (2021-2026) & (US$/Unit) Table 9. Global Inactivated Influenza Virus Vaccine Sales by Type (2027-2032) & (K Units) Table 10. Global Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Type (2027-2032) Table 11. Global Inactivated Influenza Virus Vaccine Sales by Type (2027-2032) & (US$ Million) Table 12. Global Inactivated Influenza Virus Vaccine Sales Market Share in Value by Type (2027-2032) Table 13. Global Inactivated Influenza Virus Vaccine Price by Type (2027-2032) & (US$/Unit) Table 14. North America Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 15. North America Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 17. Europe Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 21. Latin America Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (US$ Million) Table 24. Inactivated Influenza Virus Vaccine Industry Trends Table 25. Inactivated Influenza Virus Vaccine Industry Drivers Table 26. Inactivated Influenza Virus Vaccine Industry Opportunities and Challenges Table 27. Inactivated Influenza Virus Vaccine Industry Restraints Table 28. Global Inactivated Influenza Virus Vaccine Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Company (2021-2026) Table 30. Global Inactivated Influenza Virus Vaccine Sales by Company (2021-2026) & (K Units) Table 31. Global Inactivated Influenza Virus Vaccine Sales Share by Company (2021-2026) Table 32. Global Inactivated Influenza Virus Vaccine Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Inactivated Influenza Virus Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Inactivated Influenza Virus Vaccine Major Company Production Sites and Headquarters Table 35. Global Inactivated Influenza Virus Vaccine Company, Product Type & Application Table 36. Global Inactivated Influenza Virus Vaccine Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Inactivated Influenza Virus Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Inactivated Influenza Virus Vaccine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Inactivated Influenza Virus Vaccine Sales by Region (2021-2026) & (K Units) Table 41. Global Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Region (2021-2026) Table 42. Global Inactivated Influenza Virus Vaccine Sales by Region (2021-2026) & (US$ Million) Table 43. Global Inactivated Influenza Virus Vaccine Sales Market Share in Value by Region (2021-2026) Table 44. Global Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Inactivated Influenza Virus Vaccine Sales by Region (2027-2032) & (K Units) Table 46. Global Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Region (2027-2032) Table 47. Global Inactivated Influenza Virus Vaccine Sales by Region (2027-2032) & (US$ Million) Table 48. Global Inactivated Influenza Virus Vaccine Sales Market Share in Value by Region (2027-2032) Table 49. Global Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Inactivated Influenza Virus Vaccine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 52. Global Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Application (2021-2026) Table 53. Global Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (US$ Million) Table 54. Global Inactivated Influenza Virus Vaccine Sales Market Share in Value by Application (2021-2026) Table 55. Global Inactivated Influenza Virus Vaccine Price by Application (2021-2026) & (US$/Unit) Table 56. Global Inactivated Influenza Virus Vaccine Sales by Application (2027-2032) & (K Units) Table 57. Global Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Application (2027-2032) Table 58. Global Inactivated Influenza Virus Vaccine Sales by Application (2027-2032) & (US$ Million) Table 59. Global Inactivated Influenza Virus Vaccine Sales Market Share in Value by Application (2027-2032) Table 60. Global Inactivated Influenza Virus Vaccine Price by Application (2027-2032) & (US$/Unit) Table 61. North America Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 62. North America Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 64. Europe Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 68. Latin America Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (US$ Million) Table 71. CSL Company Information Table 72. CSL Business Overview Table 73. CSL Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. CSL Inactivated Influenza Virus Vaccine Product Portfolio Table 75. CSL Recent Development Table 76. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Company Information Table 77. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Business Overview Table 78. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 80. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Development Table 81. Changchun Institute of Biological Products Co., Ltd Company Information Table 82. Changchun Institute of Biological Products Co., Ltd Business Overview Table 83. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 85. Changchun Institute of Biological Products Co., Ltd Recent Development Table 86. Shanghai Institute of Biological Products Co., Ltd Company Information Table 87. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 88. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 90. Shanghai Institute of Biological Products Co., Ltd Recent Development Table 91. Johnson & Johnson Company Information Table 92. Johnson & Johnson Business Overview Table 93. Johnson & Johnson Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio Table 95. Johnson & Johnson Recent Development Table 96. Mylan Company Information Table 97. Mylan Business Overview Table 98. Mylan Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Mylan Inactivated Influenza Virus Vaccine Product Portfolio Table 100. Mylan Recent Development Table 101. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 102. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 103. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 105. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 106. Jiangsu Kangrun Biotechnology Co., Ltd Company Information Table 107. Jiangsu Kangrun Biotechnology Co., Ltd Business Overview Table 108. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 110. Jiangsu Kangrun Biotechnology Co., Ltd Recent Development Table 111. Jiangsu Jindik Biotechnology Co., Ltd Company Information Table 112. Jiangsu Jindik Biotechnology Co., Ltd Business Overview Table 113. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 115. Jiangsu Jindik Biotechnology Co., Ltd Recent Development Table 116. Pfizer Company Information Table 117. Pfizer Business Overview Table 118. Pfizer Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Pfizer Inactivated Influenza Virus Vaccine Product Portfolio Table 120. Pfizer Recent Development Table 121. Hualan Bio Vaccines Co., Ltd Company Information Table 122. Hualan Bio Vaccines Co., Ltd Business Overview Table 123. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 125. Hualan Bio Vaccines Co., Ltd Recent Development Table 126. GSK Company Information Table 127. GSK Business Overview Table 128. GSK Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. GSK Inactivated Influenza Virus Vaccine Product Portfolio Table 130. GSK Recent Development Table 131. Dalian Yalifeng Biopharmaceutical Co., Ltd Company Information Table 132. Dalian Yalifeng Biopharmaceutical Co., Ltd Business Overview Table 133. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 135. Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Development Table 136. Beijing Kexing Biological Products Co., Ltd Company Information Table 137. Beijing Kexing Biological Products Co., Ltd Business Overview Table 138. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 140. Beijing Kexing Biological Products Co., Ltd Recent Development Table 141. Emmi Chengxin Biopharmaceutical Co., Ltd Company Information Table 142. Emmi Chengxin Biopharmaceutical Co., Ltd Business Overview Table 143. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 145. Emmi Chengxin Biopharmaceutical Co., Ltd Recent Development Table 146. AstraZeneca Company Information Table 147. AstraZeneca Business Overview Table 148. AstraZeneca Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio Table 150. AstraZeneca Recent Development Table 151. Sanofi Pasteur Company Information Table 152. Sanofi Pasteur Business Overview Table 153. Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio Table 155. Sanofi Pasteur Recent Development Table 156. North America Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 157. North America Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 158. North America Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2026) Table 159. North America Inactivated Influenza Virus Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 160. North America Inactivated Influenza Virus Vaccine Sales Market Share Forecast by Country (2027-2032) Table 161. North America Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. North America Inactivated Influenza Virus Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 163. North America Inactivated Influenza Virus Vaccine Market Share by Country (2021-2026) Table 164. North America Inactivated Influenza Virus Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. North America Inactivated Influenza Virus Vaccine Market Share Forecast by Country (2027-2032) Table 166. Europe Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 167. Europe Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 168. Europe Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2026) Table 169. Europe Inactivated Influenza Virus Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 170. Europe Inactivated Influenza Virus Vaccine Sales Market Share Forecast by Country (2027-2032) Table 171. Europe Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Europe Inactivated Influenza Virus Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 173. Europe Inactivated Influenza Virus Vaccine Market Share by Country (2021-2026) Table 174. Europe Inactivated Influenza Virus Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Europe Inactivated Influenza Virus Vaccine Market Share Forecast by Country (2027-2032) Table 176. Asia-Pacific Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 177. Asia-Pacific Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 178. Asia-Pacific Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2026) Table 179. Asia-Pacific Inactivated Influenza Virus Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 180. Asia-Pacific Inactivated Influenza Virus Vaccine Sales Market Share Forecast by Country (2027-2032) Table 181. Asia-Pacific Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. Asia-Pacific Inactivated Influenza Virus Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 183. Asia-Pacific Inactivated Influenza Virus Vaccine Market Share by Country (2021-2026) Table 184. Asia-Pacific Inactivated Influenza Virus Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. Asia-Pacific Inactivated Influenza Virus Vaccine Market Share Forecast by Country (2027-2032) Table 186. Latin America Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 187. Latin America Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 188. Latin America Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2026) Table 189. Latin America Inactivated Influenza Virus Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 190. Latin America Inactivated Influenza Virus Vaccine Sales Market Share Forecast by Country (2027-2032) Table 191. Latin America Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 192. Latin America Inactivated Influenza Virus Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 193. Latin America Inactivated Influenza Virus Vaccine Market Share by Country (2021-2026) Table 194. Latin America Inactivated Influenza Virus Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 195. Latin America Inactivated Influenza Virus Vaccine Market Share Forecast by Country (2027-2032) Table 196. Middle East and Africa Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 197. Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 198. Middle East and Africa Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2026) Table 199. Middle East and Africa Inactivated Influenza Virus Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 200. Middle East and Africa Inactivated Influenza Virus Vaccine Sales Market Share Forecast by Country (2027-2032) Table 201. Middle East and Africa Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 202. Middle East and Africa Inactivated Influenza Virus Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 203. Middle East and Africa Inactivated Influenza Virus Vaccine Market Share by Country (2021-2026) Table 204. Middle East and Africa Inactivated Influenza Virus Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 205. Middle East and Africa Inactivated Influenza Virus Vaccine Market Share Forecast by Country (2027-2032) Table 206. Key Raw Materials Table 207. Raw Materials Key Suppliers Table 208. Inactivated Influenza Virus Vaccine Distributors List Table 209. Inactivated Influenza Virus Vaccine Customers List Table 210. Research Programs/Design for This Report Table 211. Authors List of This Report Table 212. Secondary Sources Table 213. Primary Sources List of Figures Figure 1. Inactivated Influenza Virus Vaccine Image Figure 2. Global Inactivated Influenza Virus Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Inactivated Influenza Virus Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Inactivated Influenza Virus Vaccine Sales (2021-2032) & (K Units) Figure 5. Whole Virus Vaccine Image Figure 6. Global Whole Virus Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 7. Subunit Vaccine Image Figure 8. Global Subunit Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Inactivated Influenza Virus Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Inactivated Influenza Virus Vaccine Market Share by Type 2025 VS 2032 Figure 11. North America Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Type in 2025 Figure 12. North America Inactivated Influenza Virus Vaccine Sales Market Share in Value by Type in 2025 Figure 13. Europe Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Type in 2025 Figure 14. Europe Inactivated Influenza Virus Vaccine Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Inactivated Influenza Virus Vaccine Sales Market Share in Value by Type in 2025 Figure 17. Latin America Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Inactivated Influenza Virus Vaccine Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Inactivated Influenza Virus Vaccine Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Inactivated Influenza Virus Vaccine Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinic Image Figure 26. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 27. Global Inactivated Influenza Virus Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Inactivated Influenza Virus Vaccine Market Share by Application 2025 VS 2032 Figure 29. North America Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Application in 2025 Figure 30. North America Inactivated Influenza Virus Vaccine Sales Market Share in Value by Application in 2025 Figure 31. Europe Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Application in 2025 Figure 32. Europe Inactivated Influenza Virus Vaccine Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Inactivated Influenza Virus Vaccine Sales Market Share in Value by Application in 2025 Figure 35. Latin America Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Inactivated Influenza Virus Vaccine Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Inactivated Influenza Virus Vaccine Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Inactivated Influenza Virus Vaccine Sales Market Share in Value by Application in 2025 Figure 39. North America Inactivated Influenza Virus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 40. North America Inactivated Influenza Virus Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Inactivated Influenza Virus Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Inactivated Influenza Virus Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Inactivated Influenza Virus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. Europe Inactivated Influenza Virus Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Inactivated Influenza Virus Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Inactivated Influenza Virus Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Inactivated Influenza Virus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Asia-Pacific Inactivated Influenza Virus Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Inactivated Influenza Virus Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Inactivated Influenza Virus Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Inactivated Influenza Virus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Latin America Inactivated Influenza Virus Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Inactivated Influenza Virus Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Inactivated Influenza Virus Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Middle East and Africa Inactivated Influenza Virus Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Inactivated Influenza Virus Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Inactivated Influenza Virus Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Inactivated Influenza Virus Vaccine Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Inactivated Influenza Virus Vaccine Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Whole Virus Vaccine
  • Subunit Vaccine
Applications
  • Hospital
  • Clinic
Companies covered
  • CSL
  • Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
  • Changchun Institute of Biological Products Co., Ltd
  • Shanghai Institute of Biological Products Co., Ltd
  • Johnson & Johnson
  • Mylan
  • Lanzhou Institute of Biological Products Co., Ltd
  • Jiangsu Kangrun Biotechnology Co., Ltd
  • Jiangsu Jindik Biotechnology Co., Ltd
  • Pfizer
  • Hualan Bio Vaccines Co., Ltd
  • GSK
  • Dalian Yalifeng Biopharmaceutical Co., Ltd
  • Beijing Kexing Biological Products Co., Ltd
  • Emmi Chengxin Biopharmaceutical Co., Ltd
  • AstraZeneca
  • Sanofi Pasteur

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Inactivated Influenza Virus Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Inactivated Influenza Virus Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Inactivated Influenza Virus Vaccine Market by Type
  6. 1.3.1 Whole Virus Vaccine
  7. 1.3.2 Subunit Vaccine
  8. 1.4 Global Inactivated Influenza Virus Vaccine Market Size by Type
  9. 1.4.1 Global Inactivated Influenza Virus Vaccine Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Inactivated Influenza Virus Vaccine Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Inactivated Influenza Virus Vaccine Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Inactivated Influenza Virus Vaccine Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Inactivated Influenza Virus Vaccine Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Inactivated Influenza Virus Vaccine Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Inactivated Influenza Virus Vaccine Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Inactivated Influenza Virus Vaccine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Inactivated Influenza Virus Vaccine Industry Trends
  2. 2.2 Inactivated Influenza Virus Vaccine Industry Drivers
  3. 2.3 Inactivated Influenza Virus Vaccine Industry Opportunities and Challenges
  4. 2.4 Inactivated Influenza Virus Vaccine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Inactivated Influenza Virus Vaccine Revenue (2021-2026)
  2. 3.2 Global Top Players by Inactivated Influenza Virus Vaccine Sales (2021-2026)
  3. 3.3 Global Top Players by Inactivated Influenza Virus Vaccine Price (2021-2026)
  4. 3.4 Global Inactivated Influenza Virus Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Inactivated Influenza Virus Vaccine Major Company Production Sites & Headquarters
  6. 3.6 Global Inactivated Influenza Virus Vaccine Company, Product Type & Application
  7. 3.7 Global Inactivated Influenza Virus Vaccine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Inactivated Influenza Virus Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Inactivated Influenza Virus Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Inactivated Influenza Virus Vaccine Tier 1, Tier 2, and Tier 3
4 Inactivated Influenza Virus Vaccine Regional Status and Outlook
  1. 4.1 Global Inactivated Influenza Virus Vaccine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Inactivated Influenza Virus Vaccine Historic Market Size by Region
  3. 4.2.1 Global Inactivated Influenza Virus Vaccine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Inactivated Influenza Virus Vaccine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Inactivated Influenza Virus Vaccine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Inactivated Influenza Virus Vaccine Forecasted Market Size by Region
  7. 4.3.1 Global Inactivated Influenza Virus Vaccine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Inactivated Influenza Virus Vaccine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Inactivated Influenza Virus Vaccine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Inactivated Influenza Virus Vaccine by Application
  1. 5.1 Inactivated Influenza Virus Vaccine Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Inactivated Influenza Virus Vaccine Market Size by Application
  5. 5.2.1 Global Inactivated Influenza Virus Vaccine Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Inactivated Influenza Virus Vaccine Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Inactivated Influenza Virus Vaccine Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Inactivated Influenza Virus Vaccine Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Inactivated Influenza Virus Vaccine Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Inactivated Influenza Virus Vaccine Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Inactivated Influenza Virus Vaccine Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Inactivated Influenza Virus Vaccine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 CSL
  2. 6.1.1 CSL Company Information
  3. 6.1.2 CSL Business Overview
  4. 6.1.3 CSL Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 CSL Inactivated Influenza Virus Vaccine Product Portfolio
  6. 6.1.5 CSL Recent Developments
  7. 6.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
  8. 6.2.1 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Company Information
  9. 6.2.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Business Overview
  10. 6.2.3 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  12. 6.2.5 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments
  13. 6.3 Changchun Institute of Biological Products Co., Ltd
  14. 6.3.1 Changchun Institute of Biological Products Co., Ltd Company Information
  15. 6.3.2 Changchun Institute of Biological Products Co., Ltd Business Overview
  16. 6.3.3 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  18. 6.3.5 Changchun Institute of Biological Products Co., Ltd Recent Developments
  19. 6.4 Shanghai Institute of Biological Products Co., Ltd
  20. 6.4.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  21. 6.4.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  22. 6.4.3 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  24. 6.4.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  25. 6.5 Johnson & Johnson
  26. 6.5.1 Johnson & Johnson Company Information
  27. 6.5.2 Johnson & Johnson Business Overview
  28. 6.5.3 Johnson & Johnson Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio
  30. 6.5.5 Johnson & Johnson Recent Developments
  31. 6.6 Mylan
  32. 6.6.1 Mylan Company Information
  33. 6.6.2 Mylan Business Overview
  34. 6.6.3 Mylan Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Mylan Inactivated Influenza Virus Vaccine Product Portfolio
  36. 6.6.5 Mylan Recent Developments
  37. 6.7 Lanzhou Institute of Biological Products Co., Ltd
  38. 6.7.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  39. 6.7.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  40. 6.7.3 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  42. 6.7.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  43. 6.8 Jiangsu Kangrun Biotechnology Co., Ltd
  44. 6.8.1 Jiangsu Kangrun Biotechnology Co., Ltd Company Information
  45. 6.8.2 Jiangsu Kangrun Biotechnology Co., Ltd Business Overview
  46. 6.8.3 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  48. 6.8.5 Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments
  49. 6.9 Jiangsu Jindik Biotechnology Co., Ltd
  50. 6.9.1 Jiangsu Jindik Biotechnology Co., Ltd Company Information
  51. 6.9.2 Jiangsu Jindik Biotechnology Co., Ltd Business Overview
  52. 6.9.3 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  54. 6.9.5 Jiangsu Jindik Biotechnology Co., Ltd Recent Developments
  55. 6.10 Pfizer
  56. 6.10.1 Pfizer Company Information
  57. 6.10.2 Pfizer Business Overview
  58. 6.10.3 Pfizer Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Pfizer Inactivated Influenza Virus Vaccine Product Portfolio
  60. 6.10.5 Pfizer Recent Developments
  61. 6.11 Hualan Bio Vaccines Co., Ltd
  62. 6.11.1 Hualan Bio Vaccines Co., Ltd Company Information
  63. 6.11.2 Hualan Bio Vaccines Co., Ltd Business Overview
  64. 6.11.3 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  66. 6.11.5 Hualan Bio Vaccines Co., Ltd Recent Developments
  67. 6.12 GSK
  68. 6.12.1 GSK Company Information
  69. 6.12.2 GSK Business Overview
  70. 6.12.3 GSK Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 GSK Inactivated Influenza Virus Vaccine Product Portfolio
  72. 6.12.5 GSK Recent Developments
  73. 6.13 Dalian Yalifeng Biopharmaceutical Co., Ltd
  74. 6.13.1 Dalian Yalifeng Biopharmaceutical Co., Ltd Company Information
  75. 6.13.2 Dalian Yalifeng Biopharmaceutical Co., Ltd Business Overview
  76. 6.13.3 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  78. 6.13.5 Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments
  79. 6.14 Beijing Kexing Biological Products Co., Ltd
  80. 6.14.1 Beijing Kexing Biological Products Co., Ltd Company Information
  81. 6.14.2 Beijing Kexing Biological Products Co., Ltd Business Overview
  82. 6.14.3 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  84. 6.14.5 Beijing Kexing Biological Products Co., Ltd Recent Developments
  85. 6.15 Emmi Chengxin Biopharmaceutical Co., Ltd
  86. 6.15.1 Emmi Chengxin Biopharmaceutical Co., Ltd Company Information
  87. 6.15.2 Emmi Chengxin Biopharmaceutical Co., Ltd Business Overview
  88. 6.15.3 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  90. 6.15.5 Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments
  91. 6.16 AstraZeneca
  92. 6.16.1 AstraZeneca Company Information
  93. 6.16.2 AstraZeneca Business Overview
  94. 6.16.3 AstraZeneca Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio
  96. 6.16.5 AstraZeneca Recent Developments
  97. 6.17 Sanofi Pasteur
  98. 6.17.1 Sanofi Pasteur Company Information
  99. 6.17.2 Sanofi Pasteur Business Overview
  100. 6.17.3 Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio
  102. 6.17.5 Sanofi Pasteur Recent Developments
7 North America by Country
  1. 7.1 North America Inactivated Influenza Virus Vaccine Sales by Country
  2. 7.1.1 North America Inactivated Influenza Virus Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Inactivated Influenza Virus Vaccine Sales by Country (2021-2026)
  4. 7.1.3 North America Inactivated Influenza Virus Vaccine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Inactivated Influenza Virus Vaccine Market Size by Country
  6. 7.2.1 North America Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Inactivated Influenza Virus Vaccine Market Size by Country (2021-2026)
  8. 7.2.3 North America Inactivated Influenza Virus Vaccine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Inactivated Influenza Virus Vaccine Sales by Country
  2. 8.1.1 Europe Inactivated Influenza Virus Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Inactivated Influenza Virus Vaccine Sales by Country (2021-2026)
  4. 8.1.3 Europe Inactivated Influenza Virus Vaccine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Inactivated Influenza Virus Vaccine Market Size by Country
  6. 8.2.1 Europe Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Inactivated Influenza Virus Vaccine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Inactivated Influenza Virus Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Inactivated Influenza Virus Vaccine Sales by Country
  2. 9.1.1 Asia-Pacific Inactivated Influenza Virus Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Inactivated Influenza Virus Vaccine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Inactivated Influenza Virus Vaccine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Inactivated Influenza Virus Vaccine Market Size by Country
  6. 9.2.1 Asia-Pacific Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Inactivated Influenza Virus Vaccine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Inactivated Influenza Virus Vaccine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Inactivated Influenza Virus Vaccine Sales by Country
  2. 10.1.1 South America Inactivated Influenza Virus Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Inactivated Influenza Virus Vaccine Sales by Country (2021-2026)
  4. 10.1.3 South America Inactivated Influenza Virus Vaccine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Inactivated Influenza Virus Vaccine Market Size by Country
  6. 10.2.1 South America Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Inactivated Influenza Virus Vaccine Market Size by Country (2021-2026)
  8. 10.2.3 South America Inactivated Influenza Virus Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country
  2. 11.1.1 Middle East and Africa Inactivated Influenza Virus Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Inactivated Influenza Virus Vaccine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Inactivated Influenza Virus Vaccine Market Size by Country
  6. 11.2.1 Middle East and Africa Inactivated Influenza Virus Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Inactivated Influenza Virus Vaccine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Inactivated Influenza Virus Vaccine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Inactivated Influenza Virus Vaccine Value Chain Analysis
  2. 12.1.1 Inactivated Influenza Virus Vaccine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Inactivated Influenza Virus Vaccine Production Mode & Process
  7. 12.2 Inactivated Influenza Virus Vaccine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Inactivated Influenza Virus Vaccine Distributors
  10. 12.2.3 Inactivated Influenza Virus Vaccine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst